GAL3 receptor antagonists for the treatment of affective disorders

The invention provides a method of treating a subject suffering from an affective disorder which comprises administering to the subject an amount of compound effective to treat the subject's affective disorder wherein the compound has the structure:

• 499
• wherein each of Y1, Y2, Y3, and Y4 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluorcalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, or C5-C7 cycloalkenyl;
• —F, —Cl, —Br, or —I;
• —NO2;
• —N3;
• —CN;
• —OR4, —OCOR4, —COR4, —NCOR4, —N(R4)2, —CON(R4)2, or —COOR4;
• aryl or heteroaryl;
• or any two of Y1, Y2, Y3 and Y4 present on adjacent carbon atoms can constitute a methylenedioxy group;
• wherein each R4 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, C5-C7 cycloalkenyl, aryl or aryl (C1-C6)alkyl;
• wherein A is A′, straight chained or branched C1-C7 alkyl, aryl, heteroaryl, aryl(C1-C6)alkyl or heteroaryl (C1-C6)alkyl;
• 500
• wherein R1 and R2 are each independently H, straight chained or branched C1-C7 alkyl, —F, —Cl, —Br, —I, —NO2, or —CN;
• wherein R3 is H, straight chained or branched C1-C7 alkyl, —F, —Cl, —Br, —I, —NO2, —CN, —OR6, aryl or heteroaryl;
• wherein R5 is straight chained or branched C1-C7 alkyl, —N(R4)2, —OR4 or aryl;
• wherein R6 is straight chained or branched C1-C7 alkyl or aryl;
• wherein B is C3-C7 cycloalkyl, C5-C7 cycloalkenyl, adamantyl, aryl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indolizinyl, indol-4-yl, indol-5-yl, indol-6-yl, indol-7-yl, isoindolyl, benzo[b]furan-4-yl, benzo[b]furan-5-yl, benzo[b]furan-6-yl, benzo[b]furan-7-yl, benzo[b]thiophen-4-yl, benzo[b]thiophen-5-yl, benzo[b]thiophen-6-yl, benzo[b]thiophen-7-yl, indazolyl, benzimidazolyl, benzo[b]thiazolyl, purinyl, imidazo[2,1-b]thiazolyl, quinolinyl, isoquinolinyl, quinazolinyl, 2,1,3-benzothiazolyl, furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, benzoxazolyl, benzisoxazolyl, cinnolinyl, quinoxalinyl, 1,8-naphthridinyl, pteridinyl, or phthalimidyl;
• provided however, if B is aryl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indolizinyl, indol-4-yl, indol-5-yl, indol-6-yl, indol-7-yl, isoindolyl, benzo[b]furan-4-yl, benzo[b]furan-5-yl, benzo[b]furan-6-yl, benzo[b]furan-7-yl, benzo[b]thiophen-4-yl, benzo[b]thiophen-5-yl, benzo[b]thiophen-6-yl, benzo[b]thiophen-7-yl, indazolyl, benzimidazolyl, benzo[b]thiazolyl, purinyl, imidazo[2,1-b]thiazolyl, quinolinyl, isoquinolinyl, quinazolinyl, 2,1,3-benzothiazolyl, furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, benzoxazolyl, benzisoxazolyl, cinnolinyl, quinoxalinyl, 1,8-napthyridinyl, pteridinyl, or phthalimidyl the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following —F, —Cl, —Br, —I, —CN, methyl, ethyl or methoxy;
• wherein n is an integer from 1 to 4 inclusive.